The global HIV diagnosis and treatment market is estimated to grow at a CAGR of 7.6%, during the forecast period. Rising incidence and prevalence rate of HIV infection across the globe coupled with the technological development of diagnostic tests, such as rapid CD4, EID test and regulatory authority such as approval of POC (point of care testing) for detection of HIV), is driving the market growth. According to the Joint United Nations Program on HIV and AIDS (UNAID), more than 36.7 million people across the globe have HIV and around 1.8 million children had HIV infection in 2017. The FDA performed the clinical value of HIV diagnostic assay and blood screening and regulates the study to create product standard and incorporated enhanced diagnostic methods to enables the safety of drugs and biologics. The multidisciplinary research program plays a vital role in the establishment of test kits, vaccines, therapeutics agents for utilization in AIDS. Government support will support the growth of the HIV diagnostics and treatment market.
To Request a Sample of our Report on HIV Diagnostics and Treatment Market: https://www.omrglobal.com/request-sample/hiv-diagnostics-and-treatment-market
The HIV diagnosis and treatment market is growing due to government initiatives, rising awareness about HIV and growing number of blood donation is the reason for the increase in a number of AIDs infection. It is a basic requirement for the treatment of HIV in underdeveloped nation need for technological equipment; however, the scarcity of funds and inaccuracy of the tests and with unskilled professionals are hampering the market growth of HIV diagnostics and treatment market.
(Get 15% Discount on Buying this Report)
A full Report of HIV Diagnostics and Treatment Market is Available at: https://www.omrglobal.com/industry-reports/hiv-diagnostics-and-treatment-market
HIV Diagnostics and Treatment Market Segmentation
By Test Type
· Antibody Tests
· HIV-1 Screening Tests
· HIV-1 Antibody Confirmatory Tests
· HIV-2 & Group O Diagnostics Tests
· Viral Identification Assays
· CD4 Testing
· Viral Load Testing
· Early Infant Diagnostics
By Diagnostics Products
· Kits and Reagents
· Instruments
By Treatment
· Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS)
· Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIS)
· Integrase Inhibitors
· Others (Protease Inhibitors (PIS))
By End-User
· Diagnostics Laboratory
· Hospitals
· Blood Banks
· Home Care Settings
· Others (Academic and Research Institutes)
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
